Last reviewed · How we verify

Hibiclens

University of Missouri-Columbia · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Hibiclens is a Small molecule drug developed by University of Missouri-Columbia. It is currently FDA-approved.

Hibiclens, a small molecule, is a disinfectant and antiseptic used for skin disinfection before surgery and to disinfect surgical instruments. It is also used in various medical conditions, including COPD, CHF, and dialysis, as well as for conditions such as gingival bleeding and malocclusion.

At a glance

Generic nameHibiclens
SponsorUniversity of Missouri-Columbia
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hibiclens

What is Hibiclens?

Hibiclens is a Small molecule drug developed by University of Missouri-Columbia.

Who makes Hibiclens?

Hibiclens is developed and marketed by University of Missouri-Columbia (see full University of Missouri-Columbia pipeline at /company/university-of-missouri-columbia).

What development phase is Hibiclens in?

Hibiclens is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing